Phase II trial of high-dose dexamethasone for untreated patients with primary systemic amyloidosis

被引：30

作者：

Gertz, MA ^{[1
]}

Lacy, MQ ^{[1
]}

Lust, JA ^{[1
]}

Greipp, PR ^{[1
]}

Witzig, TE ^{[1
]}

Kyle, RA ^{[1
]}

机构：

[1] Mayo Clin & Mayo Fdn, Dysproteinemia Clin, Rochester, MN 55905 USA

来源：

MEDICAL ONCOLOGY | 1999年 / 16卷 / 02期

关键词：

amyloidosis; corticosteroid therapy; dexamethasone therapy; nephrotic syndrome;

D O I：

10.1007/BF02785843

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Primary systemic amyloidosis is the disorder that results from the deposition of insoluble immunoglobulin light chain fragments. Patients seen within 30 days of diagnosis have a median survival of 13 months. Patients treated with melphalan and prednisone have a median survival of 17 months. There is a need for new therapies. A prospective study was undertaken of high-dose dexamethasone in the treatment of 25 patients with previously untreated primary systemic amyloidosis. Treatment was similar to that given to patients with multiple myeloma. In this cohort, three patients showed objective regression with organ-specific improvement of the disease. The median survival of the entire group was 13.8 months. High-dose dexamethasone is of occasional benefit in patients with amyloidosis but does not appear to be superior to melphalan and prednisone chemotherapy.

引用

页码：104 / 109

页数：6

共 47 条

[1]

ADAM Z, 1994, ACTA MED AUST, V21, P137

[2]

Adam Z, 1994, Vnitr Lek, V40, P595

[3]

ALEXANIAN R, 1986, ANN INTERN MED, V105, P8, DOI 10.7326/0003-4819-105-1-8

[4]

ALEXANIAN R, 1992, BLOOD, V80, P887

[5]

Bellotti V, 1996, NEPHROL DIAL TRANSPL, V11, P53

[6] Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism [J].

Chauhan, D ;

Pandey, P ;

Ogata, A ;

Teoh, G ;

Treon, S ;

Urashima, M ;

Kharbanda, S ;

Anderson, KC .

ONCOGENE, 1997, 15 (07) :837-843

[7] Inhibition of myeloma cell growth by dexamethasone and all-trans retinoic acid: Synergy through modulation of interleukin-6 autocrine loop at multiple sites [J].

Chen, YH ;

Desai, P ;

Shiao, RT ;

Lavelle, D ;

Haleem, A ;

Chen, J .

BLOOD, 1996, 87 (01) :314-323

[8]

CHIDIAC TA, 1997, PROG P AM SOC CLIN O, V16, pA12

[9] RESOLUTION OF PRIMARY AMYLOIDOSIS DURING CHEMOTHERAPY - STUDIES IN A PATIENT WITH NEPHROTIC SYNDROME [J].

COHEN, HJ ;

LESSIN, LS ;

HALLAL, J ;

BURKHOLDER, P .

ANNALS OF INTERNAL MEDICINE, 1975, 82 (04) :466-473

[10] Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: One-year follow-up in five patients [J].

Comenzo, RL ;

Vosburgh, E ;

Simms, RW ;

Bergethon, P ;

Sarnacki, D ;

Finn, K ;

Dubrey, S ;

Faller, DV ;

Wright, DG ;

Falk, RH ;

Skinner, M .

BLOOD, 1996, 88 (07) :2801-2806

← 1 2 3 4 5 →